XENE
Xenon Pharmaceuticals Inc.
Price Chart
Latest Quote
$67.08
-0.63 (-0.94%)
Current Price
| Previous Close | $67.71 |
| Open | $67.70 |
| Day High | $67.76 |
| Day Low | $66.72 |
| Volume | 127,931 |
Stock Information
| Shares Outstanding | 96.67M |
| Total Debt | $7.49M |
| Cash Equivalents | $1.09B |
| Net Income | $-383.16M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $6.60B |
| EPS (TTM) | $-4.79 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $5.51B |
| Income | $-383.16M |
| Book/sh | $7.27 |
| Cash/sh | $11.33 |
| Employees | 358 |
Financial Ratios
| Quick Ratio | 27.52 |
| Current Ratio | 27.79 |
| Debt/Eq | 0.56 |
Returns & Margins
| ROA | -24.22% |
| ROE | -37.53% |
Ownership
| Insider Ownership | 0.12% |
| Institutional Ownership | 107.47% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -13.63 |
| P/B | 9.39 |
Analyst Data
| Recommendation | none |
| Target Price | $80.56 |
Technical Indicators
| SMA20 | $62.39 |
| SMA50 | $57.30 |
| SMA200 | $48.87 |
| RSI | 73.33 |
| ATR | 2.7581 |
| Shares Float | 90.76M |
| Short Float | 6.48% |
| Short Ratio | 3.56 |
| Volatility | 0.61 |
| Rel Volume | 0.66 |
Performance History
| Week | -0.96% |
| Month | +31.29% |
| Quarter | +16.82% |
| 6 Months | +64.17% |
| YTD | +53.43% |
| Year | +115.88% |
| 3 Years | +76.38% |
| 5 Years | +266.79% |
| 10 Years | +781.91% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $68.26 | 1,342,600 |
| 2026-07-16 | $66.98 | 1,501,900 |
| 2026-07-15 | $67.71 | 772,000 |
| 2026-07-14 | $67.30 | 1,046,000 |
| 2026-07-13 | $67.72 | 1,527,800 |
| 2026-07-10 | $68.92 | 1,535,900 |
| 2026-07-09 | $70.96 | 2,587,200 |
| 2026-07-08 | $69.95 | 4,764,000 |
| 2026-07-07 | $63.37 | 1,442,800 |
| 2026-07-06 | $60.54 | 1,734,600 |
| 2026-07-02 | $60.96 | 1,462,600 |
| 2026-07-01 | $60.30 | 1,271,400 |
| 2026-06-30 | $60.36 | 1,251,700 |
| 2026-06-29 | $60.13 | 1,689,800 |
| 2026-06-26 | $59.74 | 8,840,000 |
| 2026-06-25 | $56.78 | 1,116,000 |
| 2026-06-24 | $55.58 | 1,425,200 |
| 2026-06-23 | $54.61 | 1,498,300 |
| 2026-06-22 | $54.79 | 1,856,200 |
| 2026-06-18 | $52.91 | 1,927,700 |
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
đ° Latest News
Why Wall Street Is Growing More Cautious on Biohaven (BHVN)
Insider Monkey âĸ 2026-07-06T17:20:49Z
Xenon Pharmaceuticals Stock Gains 22% in Six Months: Here's Why
Zacks âĸ 2026-06-23T14:59:00Z
Assessing Xenon Pharmaceuticals (XENE) Valuation After Recent Share Price Pullback And Modest Undervaluation Estimate
Simply Wall St. âĸ 2026-06-11T17:11:59Z
JPMorgan Raises its Price Target on Xenon Pharmaceuticals (XENE)
Insider Monkey âĸ 2026-05-23T02:31:38Z
What to Know About This Fundâs New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing
Motley Fool âĸ 2026-05-18T17:44:01Z
A Look At Xenon Pharmaceuticals (XENE) Valuation After Phase 3 X TOLE2 Success And Extended Cash Runway
Simply Wall St. âĸ 2026-05-11T15:13:46Z
Did Positive X-TOLE2 Data and a Major Cash Raise Just Shift Xenon Pharmaceuticals' (XENE) Investment Narrative?
Simply Wall St. âĸ 2026-05-11T08:13:04Z
Xenon Pharmaceuticals Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-09T08:07:05Z
Xenon Q1 Earnings Match Estimates, Pipeline Development in Focus
Zacks âĸ 2026-05-08T16:47:00Z
Xenon (XENE) Q1 2026 Earnings Transcript
Motley Fool âĸ 2026-05-07T22:20:16Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $7,500,000 | $0 | $0 | $9,434,000 |
| Operating Revenue | $7,500,000 | $0 | $0 | $9,434,000 |
| Expenses | ||||
| Total Expenses | $380,570,000 | $279,298,000 | $214,054,000 | $138,577,000 |
| Other Income Expense | $1,348,000 | $-1,064,000 | $3,749,000 | $-4,825,000 |
| Net Non Operating Interest Income Expense | $26,828,000 | $41,943,000 | $27,620,000 | $8,713,000 |
| Operating Expense | $380,570,000 | $279,298,000 | $214,054,000 | $138,577,000 |
| General And Administrative Expense | $79,632,000 | $68,904,000 | $46,542,000 | $32,810,000 |
| Interest Expense | - | - | - | $0 |
| Interest Expense Non Operating | - | - | - | $0 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-345,910,000 | $-234,330,000 | $-182,393,000 | $-125,373,000 |
| Net Interest Income | $26,828,000 | $41,943,000 | $27,620,000 | $8,713,000 |
| Interest Income | $26,828,000 | $41,943,000 | $27,620,000 | $8,713,000 |
| Normalized Income | $-347,055,800 | $-233,284,088 | $-186,134,502 | $-121,812,632 |
| Net Income From Continuing And Discontinued Operation | $-345,910,000 | $-234,330,000 | $-182,393,000 | $-125,373,000 |
| Total Operating Income As Reported | $-373,070,000 | $-279,298,000 | $-214,054,000 | $-129,143,000 |
| Net Income Common Stockholders | $-345,910,000 | $-234,330,000 | $-182,393,000 | $-124,936,000 |
| Net Income | $-345,910,000 | $-234,330,000 | $-182,393,000 | $-125,373,000 |
| Net Income Including Noncontrolling Interests | $-345,910,000 | $-234,330,000 | $-182,393,000 | $-125,373,000 |
| Net Income Continuous Operations | $-345,910,000 | $-234,330,000 | $-182,393,000 | $-125,373,000 |
| Pretax Income | $-344,894,000 | $-238,419,000 | $-182,685,000 | $-125,255,000 |
| Interest Income Non Operating | $26,828,000 | $41,943,000 | $27,620,000 | $8,713,000 |
| Operating Income | $-373,070,000 | $-279,298,000 | $-214,054,000 | $-129,143,000 |
| Special Income Charges | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-4.36 | $-3.01 | $-2.73 | $-2.06 |
| Basic EPS | $-4.36 | $-3.01 | $-2.73 | $-2.06 |
| Other | ||||
| Tax Effect Of Unusual Items | $202,200 | $-18,088 | $7,498 | $-1,264,632 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-371,875,000 | $-275,674,000 | $-215,742,000 | $-122,913,000 |
| Total Unusual Items | $1,348,000 | $-1,064,000 | $3,749,000 | $-4,825,000 |
| Total Unusual Items Excluding Goodwill | $1,348,000 | $-1,064,000 | $3,749,000 | $-4,825,000 |
| Reconciled Depreciation | $2,543,000 | $2,560,000 | $2,061,000 | $1,405,000 |
| EBITDA (Bullshit earnings) | $-370,527,000 | $-276,738,000 | $-211,993,000 | $-127,738,000 |
| EBIT | $-373,070,000 | $-279,298,000 | $-214,054,000 | $-129,143,000 |
| Diluted Average Shares | $79,253,751 | $77,894,643 | $66,889,005 | $60,542,142 |
| Basic Average Shares | $79,253,751 | $77,894,643 | $66,889,005 | $60,542,142 |
| Diluted NI Availto Com Stockholders | $-345,910,000 | $-234,330,000 | $-182,393,000 | $-124,936,000 |
| Tax Provision | $1,016,000 | $-4,089,000 | $-292,000 | $118,000 |
| Gain On Sale Of Security | $1,348,000 | $-1,064,000 | $3,749,000 | $-4,825,000 |
| Research And Development | $300,938,000 | $210,394,000 | $167,512,000 | $105,767,000 |
| Selling General And Administration | $79,632,000 | $68,904,000 | $46,542,000 | $32,810,000 |
| Other Gand A | $79,632,000 | $68,904,000 | $46,542,000 | $32,810,000 |
| Preferred Stock Dividends | - | - | - | $-437,000 |
Fetched: 2026-06-28
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $581,760,000 | $754,903,000 | $927,921,000 | $721,497,000 |
| Total Assets | $633,163,000 | $798,139,000 | $964,798,000 | $754,146,000 |
| Total Non Current Assets | $72,514,000 | $162,875,000 | $319,836,000 | $153,848,000 |
| Non Current Prepaid Assets | $7,151,000 | $7,496,000 | $7,396,000 | $7,751,000 |
| Non Current Deferred Assets | $12,864,000 | $9,666,000 | $802,000 | $509,000 |
| Non Current Deferred Taxes Assets | $12,864,000 | $9,666,000 | $802,000 | $509,000 |
| Investmentin Financial Assets | $37,152,000 | $127,496,000 | $292,792,000 | $128,682,000 |
| Current Assets | $560,649,000 | $635,264,000 | $644,962,000 | $600,298,000 |
| Other Current Assets | $10,392,000 | $6,890,000 | $6,006,000 | $7,225,000 |
| Receivables | $1,371,000 | $1,469,000 | $874,000 | $986,000 |
| Accounts Receivable | $1,371,000 | $1,469,000 | $874,000 | $986,000 |
| Cash Cash Equivalents And Short Term Investments | $548,886,000 | $626,905,000 | $638,082,000 | $592,087,000 |
| Cash And Cash Equivalents | $199,163,000 | $142,712,000 | $148,643,000 | $57,242,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $7,944,000 | $9,015,000 | $10,903,000 | $10,435,000 |
| Long Term Debt And Capital Lease Obligation | $6,412,000 | $7,646,000 | $9,604,000 | $9,947,000 |
| Current Debt And Capital Lease Obligation | $1,532,000 | $1,369,000 | $1,299,000 | $488,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $51,403,000 | $43,236,000 | $36,877,000 | $32,649,000 |
| Total Non Current Liabilities Net Minority Interest | $9,611,000 | $7,646,000 | $9,604,000 | $9,947,000 |
| Other Non Current Liabilities | $3,199,000 | - | - | - |
| Current Liabilities | $41,792,000 | $35,590,000 | $27,273,000 | $22,702,000 |
| Payables And Accrued Expenses | $25,800,000 | $24,293,000 | $18,549,000 | $16,391,000 |
| Payables | $4,198,000 | $10,756,000 | $8,945,000 | $8,491,000 |
| Total Tax Payable | $313,000 | $5,686,000 | $347,000 | - |
| Accounts Payable | $3,885,000 | $5,070,000 | $8,598,000 | $8,491,000 |
| Current Deferred Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $581,760,000 | $754,903,000 | $927,921,000 | $721,497,000 |
| Total Equity Gross Minority Interest | $581,760,000 | $754,903,000 | $927,921,000 | $721,497,000 |
| Stockholders Equity | $581,760,000 | $754,903,000 | $927,921,000 | $721,497,000 |
| Gains Losses Not Affecting Retained Earnings | $335,000 | $-1,612,000 | $-77,000 | $-3,000,000 |
| Other Equity Adjustments | $335,000 | $-1,612,000 | $-77,000 | $-3,000,000 |
| Retained Earnings | $-1,245,380,000 | $-899,470,000 | $-665,140,000 | $-482,747,000 |
| Preferred Stock Equity | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $80,010,790 | $76,416,086 | $75,370,977 | $62,587,701 |
| Share Issued | $80,010,790 | $76,416,086 | $75,370,977 | $62,587,701 |
| Tangible Book Value | $581,760,000 | $754,903,000 | $927,921,000 | $721,497,000 |
| Invested Capital | $581,760,000 | $754,903,000 | $927,921,000 | $721,497,000 |
| Working Capital | $518,857,000 | $599,674,000 | $617,689,000 | $577,596,000 |
| Capital Lease Obligations | $7,944,000 | $9,015,000 | $10,903,000 | $10,435,000 |
| Total Capitalization | $581,760,000 | $754,903,000 | $927,921,000 | $721,497,000 |
| Additional Paid In Capital | $228,234,000 | $199,149,000 | $156,764,000 | $142,108,000 |
| Capital Stock | $1,598,571,000 | $1,456,836,000 | $1,436,374,000 | $1,065,136,000 |
| Common Stock | $1,598,571,000 | $1,456,836,000 | $1,436,374,000 | $1,065,136,000 |
| Long Term Capital Lease Obligation | $6,412,000 | $7,646,000 | $9,604,000 | $9,947,000 |
| Current Capital Lease Obligation | $1,532,000 | $1,369,000 | $1,299,000 | $488,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $14,460,000 | $9,928,000 | $7,425,000 | $5,823,000 |
| Current Accrued Expenses | $21,602,000 | $13,537,000 | $9,604,000 | $7,900,000 |
| Investments And Advances | $37,152,000 | $127,496,000 | $292,792,000 | $128,682,000 |
| Available For Sale Securities | $37,152,000 | $127,496,000 | $292,792,000 | $128,682,000 |
| Net PPE | $15,347,000 | $18,217,000 | $18,846,000 | $16,906,000 |
| Accumulated Depreciation | $-15,449,000 | $-13,464,000 | $-11,251,000 | $-8,705,000 |
| Gross PPE | $30,796,000 | $31,681,000 | $30,097,000 | $25,611,000 |
| Leases | $9,407,000 | $9,363,000 | $9,019,000 | $4,203,000 |
| Other Properties | $12,127,000 | $11,631,000 | $9,111,000 | $8,921,000 |
| Machinery Furniture Equipment | $2,636,000 | $2,748,000 | $2,774,000 | $2,081,000 |
| Buildings And Improvements | $6,626,000 | $7,939,000 | $9,193,000 | $10,406,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $349,723,000 | $484,193,000 | $489,439,000 | $534,845,000 |
| Treasury Shares Number | - | - | $0 | - |
| Preferred Stock | - | - | - | $0 |
| Current Deferred Revenue | - | - | - | - |
Fetched: 2026-06-28
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-279,917,000 | $-184,464,000 | $-156,729,000 | $-103,922,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-279,118,000 | $-181,389,000 | $-151,112,000 | $-101,028,000 |
| Cash Flow From Continuing Operating Activities | $-279,118,000 | $-181,389,000 | $-151,112,000 | $-101,028,000 |
| Operating Gains Losses | $698,000 | $745,000 | $-640,000 | $2,729,000 |
| Investing Activities | ||||
| Capital Expenditure | $-799,000 | $-3,075,000 | $-5,617,000 | $-2,894,000 |
| Investing Cash Flow | $217,998,000 | $165,000,000 | $-111,385,000 | $-293,405,000 |
| Cash Flow From Continuing Investing Activities | $217,998,000 | $165,000,000 | $-111,385,000 | $-293,405,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $112,151,000 | $12,083,000 | $353,487,000 | $277,766,000 |
| Financing Cash Flow | $117,113,000 | $12,130,000 | $353,522,000 | $278,471,000 |
| Cash Flow From Continuing Financing Activities | $117,113,000 | $12,130,000 | $353,522,000 | $278,471,000 |
| Net Common Stock Issuance | $112,151,000 | $12,083,000 | $353,487,000 | $277,766,000 |
| Common Stock Issuance | $112,151,000 | $12,083,000 | $353,487,000 | $277,766,000 |
| Other | ||||
| End Cash Position | $199,163,000 | $142,712,000 | $148,643,000 | $57,242,000 |
| Beginning Cash Position | $142,712,000 | $148,643,000 | $57,242,000 | $175,688,000 |
| Effect Of Exchange Rate Changes | $458,000 | $-1,672,000 | $376,000 | $-2,484,000 |
| Changes In Cash | $55,993,000 | $-4,259,000 | $91,025,000 | $-115,962,000 |
| Proceeds From Stock Option Exercised | $4,962,000 | $47,000 | $35,000 | $705,000 |
| Net Investment Purchase And Sale | $218,797,000 | $168,075,000 | $-105,768,000 | $-290,511,000 |
| Sale Of Investment | $574,454,000 | $700,343,000 | $688,139,000 | $260,626,000 |
| Purchase Of Investment | $-355,657,000 | $-532,268,000 | $-793,907,000 | $-551,137,000 |
| Net PPE Purchase And Sale | $-799,000 | $-3,075,000 | $-5,617,000 | $-2,894,000 |
| Purchase Of PPE | $-799,000 | $-3,075,000 | $-5,617,000 | $-2,894,000 |
| Change In Working Capital | $4,360,000 | $5,713,000 | $5,902,000 | $-1,276,000 |
| Change In Other Current Liabilities | $1,902,000 | $-1,220,000 | $267,000 | $-600,000 |
| Change In Payables And Accrued Expense | $5,511,000 | $8,531,000 | $3,931,000 | $8,062,000 |
| Change In Prepaid Assets | $-3,157,000 | $-984,000 | $1,574,000 | $-10,495,000 |
| Change In Receivables | $104,000 | $-614,000 | $130,000 | $1,757,000 |
| Changes In Account Receivables | $104,000 | $-614,000 | $130,000 | $1,757,000 |
| Other Non Cash Items | $1,313,000 | $1,254,000 | $1,213,000 | $819,000 |
| Stock Based Compensation | $53,707,000 | $50,717,000 | $32,372,000 | $20,376,000 |
| Unrealized Gain Loss On Investment Securities | $0 | $0 | $-3,550,000 | $2,934,000 |
| Amortization Of Securities | $7,369,000 | $816,000 | $-5,785,000 | $-2,598,000 |
| Deferred Tax | $-3,198,000 | $-8,864,000 | $-292,000 | $-44,000 |
| Deferred Income Tax | $-3,198,000 | $-8,864,000 | $-292,000 | $-44,000 |
| Depreciation Amortization Depletion | $2,543,000 | $2,560,000 | $2,061,000 | $1,405,000 |
| Depreciation And Amortization | $2,543,000 | $2,560,000 | $2,061,000 | $1,405,000 |
| Depreciation | $2,543,000 | $2,560,000 | $2,061,000 | $1,405,000 |
| Gain Loss On Investment Securities | $625,000 | - | - | $2,934,000 |
| Net Foreign Currency Exchange Gain Loss | $73,000 | $745,000 | $-640,000 | $2,729,000 |
| Net Income From Continuing Operations | $-345,910,000 | $-234,330,000 | $-182,393,000 | $-125,373,000 |
| Repayment Of Debt | - | - | - | $0 |
| Interest Paid Supplemental Data | - | - | - | $0 |
| Net Issuance Payments Of Debt | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Payments | - | - | - | $0 |
| Change In Other Working Capital | - | - | - | - |
Fetched: 2026-06-28